Evidence map›Paper›PMID 29540148›Full record

ArticleBMC molecular biology2018

A protocol for custom CRISPR Cas9 donor vector construction to truncate genes in mammalian cells using pcDNA3 backbone.

Neftali Vazquez, Lilia Sanchez, Rebecca Marks, Eduardo Martinez, Victor Fanniel, Alma Lopez, Andrea Salinas, Itzel Flores, Jesse Hirschmann, Robert Gilkerson and 5 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in BMC molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.Journal of cancer research and clinical oncology · 2020
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Neftali VazquezDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Lilia SanchezDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Rebecca MarksDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Eduardo MartinezDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Victor FannielDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Alma LopezDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Andrea SalinasDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Itzel FloresDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Jesse HirschmannDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Robert GilkersonDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Erin SchuenzelDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Robert DearthDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Reginald HalabyDepartment of Biology, Montclair State University, 1 Normal Ave., Montclair, NJ, 07043, USA.
Wendy Innis-WhitehouseSchool of Medicine, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA.
Megan KeniryDepartment of Biology, University of Texas-Rio Grande Valley, 1201 W. University Dr., Edinburg, TX, 78539, USA. megan.keniry@utrgv.edu.ORCID http://orcid.org/0000-0002-4952-3545
The University of Texas Rio Grande Valley · USMontclair State University · US

Funding

Interaction of mitochondrial fusion and transmembrane potential in diabetic cardiovascular damageSC3GM116669 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI GILKERSON, ROBERT W · 2016 to 2023
$872k
Howard Hughes Medical Institute HHMI 52007568National Institute of Food and Agriculture USDA H.S.I. 2016-38422-25760National Institute of Food and Agriculture USDA Step 2 2015-38422-24061National Science Foundation 1463991National Science Foundation NSF 1463991National Science Foundation NSF Advance 1209210NIGMS NIH HHS NIH 1SC3GM11666901NIGMS NIH HHS NIH 5R25GM10086606NIGMS NIH HHS SC3 GM116669UTRGV COS UTRGV College of Sciences (COS) Seed Grant
6 · The paper itself

Abstract

backgroundClustered regularly interspaced short palindromic repeat (CRISPR) RNA-guided adaptive immune systems are found in prokaryotes to defend cells from foreign DNA. CRISPR Cas9 systems have been modified and employed as genome editing tools in wide ranging organisms. Here, we provide a detailed protocol to truncate genes in mammalian cells using CRISPR Cas9 editing. We describe custom donor vector construction using Gibson assembly with the commonly utilized pcDNA3 vector as the backbone.

resultsWe describe a step-by-step method to truncate genes of interest in mammalian cell lines using custom-made donor vectors. Our method employs 2 guide RNAs, mutant Cas9D10A nickase (Cas9 = CRISPR associated sequence 9), and a custom-made donor vector for homologous recombination to precisely truncate a gene of interest with a selectable neomycin resistance cassette (NPTII: Neomycin Phosphotransferase II). We provide a detailed protocol on how to design and construct a custom donor vector using Gibson assembly (and the commonly utilized pcDNA3 vector as the backbone) allowing researchers to obtain specific gene modifications of interest (gene truncation, gene deletion, epitope tagging or knock-in mutation). Selection of mutants in mammalian cell lines with G418 (Geneticin) combined with several screening methods: western blot analysis, polymerase chain reaction, and Sanger sequencing resulted in streamlined mutant isolation. Proof of principle experiments were done in several mammalian cell lines.

conclusionsHere we describe a detailed protocol to employ CRISPR Cas9 genome editing to truncate genes of interest using the commonly employed expression vector pcDNA3 as the backbone for the donor vector. Providing a detailed protocol for custom donor vector design and construction will enable researchers to develop unique genome editing tools. To date, detailed protocols for CRISPR Cas9 custom donor vector construction are limited (Lee et al. in Sci Rep 5:8572, 2015; Ma et al. in Sci Rep 4:4489, 2014). Custom donor vectors are commercially available, but can be expensive. Our goal is to share this protocol to aid researchers in performing genetic investigations that require custom donor vectors for specialized applications (specific gene truncations, knock-in mutations, and epitope tagging applications).

Indexed as

CRISPR-Cas SystemsCell LineDeoxyribonuclease IForkhead Box Protein O3Gene EditingGenetic VectorsHEK293 CellsHomologous RecombinationHumansMaleMutationPlasmidsRNA, Guide, CRISPR-Cas SystemsDeoxyribonuclease IForkhead Box Protein O3FOXO3 protein, humanRNA, Guide, CRISPR-Cas SystemsCRISPR Cas9Custom donor vector design and constructionMammalian cell lines

Identifiers

PMID29540148
PMCPMC5853148
OpenAlexW2804620865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.